Keratosis Pilaris-Like Eruption During Chronic Myeloid Leukemia Treatment With Tyrosine Kinase Inhibitors: A Literature Review And Case Report On Imatinib

The document reviews the occurrence of keratosis pilaris (KP)-like eruptions in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs), focusing on a case involving imatinib. It highlights that such skin reactions, though rare with imatinib, are more common with second-generation TKIs like nilotinib and dasatinib. In a study of 39 CML patients, 23% developed extensive KP, 41% had scalp alopecia, and 38.5% experienced body hair loss. Histopathological examinations showed follicular atrophy and perifollicular fibrosis. The review underscores the importance of recognizing and managing these dermatological side effects in CML patients treated with TKIs.